OBJECTIVES: The aim of this study was to evaluate the clinical implication of tumour spread through air spaces (STAS) as a prognostic factor in pathological stage I lung adenocarcinoma treated with lobectomy and to identify related parameters. METHODS: Medical records of patients who underwent pulmonary lobectomy for stage I (American Joint Committee on Cancers eighth edition) lung adenocarcinomas between 2012 and February 2018 at our institutions were reviewed retrospectively. Patients with minimally invasive adenocarcinomas and tumours ≥3 cm in size were excluded. Included patients were classified into STAS (+) and STAS (-) groups. Clinical implications of STAS and recurrence in patients were investigated. RESULTS: A total of 109 patients was analysed: 41 (37.6%) in the STAS (+) and 68 (62.4%) in the STAS (-) group. STAS was associated with larger consolidation diameter on chest tomography (≥1.5 cm; P = 0.006) or a higher invasive ratio (≥85%; P = 0.012) and presence of a micropapillary pattern in multivariable analysis (P = 0.003) The recurrence-free survival curve showed statistical difference (P = 0.008) with 3-year survival rates of 73.0% (9 patients) and 96.8% (2 patients) in the STAS (+) and STAS (-) group, respectively. However, no statistical significance was observed in the lung cancer-related survival curve (P = 0.648). The presence of STAS was an independent risk factor for recurrence in multivariable analysis (hazard ratio = 5.9, P = 0.031). CONCLUSIONS: The presence of STAS could be an important risk factor for recurrence in patients with early-stage invasive lung adenocarcinoma treated with pulmonary lobectomy.
OBJECTIVES: The aim of this study was to evaluate the clinical implication of tumour spread through air spaces (STAS) as a prognostic factor in pathological stage I lung adenocarcinoma treated with lobectomy and to identify related parameters. METHODS: Medical records of patients who underwent pulmonary lobectomy for stage I (American Joint Committee on Cancers eighth edition) lung adenocarcinomas between 2012 and February 2018 at our institutions were reviewed retrospectively. Patients with minimally invasive adenocarcinomas and tumours ≥3 cm in size were excluded. Included patients were classified into STAS (+) and STAS (-) groups. Clinical implications of STAS and recurrence in patients were investigated. RESULTS: A total of 109 patients was analysed: 41 (37.6%) in the STAS (+) and 68 (62.4%) in the STAS (-) group. STAS was associated with larger consolidation diameter on chest tomography (≥1.5 cm; P = 0.006) or a higher invasive ratio (≥85%; P = 0.012) and presence of a micropapillary pattern in multivariable analysis (P = 0.003) The recurrence-free survival curve showed statistical difference (P = 0.008) with 3-year survival rates of 73.0% (9 patients) and 96.8% (2 patients) in the STAS (+) and STAS (-) group, respectively. However, no statistical significance was observed in the lung cancer-related survival curve (P = 0.648). The presence of STAS was an independent risk factor for recurrence in multivariable analysis (hazard ratio = 5.9, P = 0.031). CONCLUSIONS: The presence of STAS could be an important risk factor for recurrence in patients with early-stage invasive lung adenocarcinoma treated with pulmonary lobectomy.
Authors: William D Travis; Hisao Asamura; Alexander A Bankier; Mary Beth Beasley; Frank Detterbeck; Douglas B Flieder; Jin Mo Goo; Heber MacMahon; David Naidich; Andrew G Nicholson; Charles A Powell; Mathias Prokop; Ramón Rami-Porta; Valerie Rusch; Paul van Schil; Yasushi Yatabe Journal: J Thorac Oncol Date: 2016-04-21 Impact factor: 15.609
Authors: Erik Thunnissen; Hans J L G Blaauwgeers; Erienne M V de Cuba; Ching Yong Yick; Douglas B Flieder Journal: Arch Pathol Lab Med Date: 2016-03 Impact factor: 5.534
Authors: Hans Blaauwgeers; Douglas Flieder; Arne Warth; Alexander Harms; Kim Monkhorst; Birgit Witte; Erik Thunnissen Journal: Am J Surg Pathol Date: 2017-09 Impact factor: 6.394
Authors: Kyuichi Kadota; Jun-Ichi Nitadori; Camelia S Sima; Hideki Ujiie; Nabil P Rizk; David R Jones; Prasad S Adusumilli; William D Travis Journal: J Thorac Oncol Date: 2015-05 Impact factor: 15.609
Authors: Y Makimoto; K Nabeshima; H Iwasaki; T Miyoshi; S Enatsu; T Shiraishi; A Iwasaki; T Shirakusa; M Kikuchi Journal: Histopathology Date: 2005-06 Impact factor: 5.087
Authors: Takashi Eguchi; Koji Kameda; Shaohua Lu; Matthew J Bott; Kay See Tan; Joseph Montecalvo; Jason C Chang; Natasha Rekhtman; David R Jones; William D Travis; Prasad S Adusumilli Journal: J Thorac Oncol Date: 2018-09-19 Impact factor: 15.609
Authors: Massimiliano Bassi; Andrea Russomando; Jacopo Vannucci; Andrea Ciardiello; Miriam Dolciami; Paolo Ricci; Angelina Pernazza; Giulia D'Amati; Carlo Mancini Terracciano; Riccardo Faccini; Sara Mantovani; Federico Venuta; Cecilia Voena; Marco Anile Journal: Transl Lung Cancer Res Date: 2022-04